Repurposing of nitroxoline as a potential anticancer agent against human prostate cancer - A crucial role on AMPK/mTOR signaling pathway and the interplay with Chk2 activation

Oncotarget

Volumn 6, Issue 37, 2015, Pages 39806-39820

  Chang, Wei Ling ^a,b   Hsu, Lih Ching ^b   Leu, Wohn Jenn ^b   Chen, Ching Shih ^a   Guh, Jih Hwa ^b  

^a OHIO STATE UNIVERSITY   (United States)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

AMPK mTOR signaling; Chk2; Cyclin D1 Rb Cdc25A axis; G1 arrest; Nitroxoline

Indexed keywords

CDC25A PROTEIN; CELL CYCLE PROTEIN; CELL DNA; CHECKPOINT KINASE 1; CHECKPOINT KINASE 2; CYCLIN D1; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MAMMALIAN TARGET OF RAPAMYCIN; NITROXOLINE; RETINOBLASTOMA PROTEIN; S6 KINASE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CDC25A PROTEIN, HUMAN; CHEK2 PROTEIN, HUMAN; NITROQUINOLINE DERIVATIVE; PROTEIN TYROSINE PHOSPHATASE; TARGET OF RAPAMYCIN KINASE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL ENERGY; CELL PROTECTION; CONTROLLED STUDY; DNA DAMAGE; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME REGULATION; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; PROSTATE CANCER; PROTEIN BINDING; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; CELL PROLIFERATION; DRUG EFFECTS; DRUG REPOSITIONING; FLUORESCENCE MICROSCOPY; GENETICS; MALE; METABOLISM; PATHOLOGY; PROSTATE TUMOR; RNA INTERFERENCE; TUMOR CELL LINE; WESTERN BLOTTING;

AMP-ACTIVATED PROTEIN KINASES; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CDC25 PHOSPHATASES; CELL LINE, TUMOR; CELL PROLIFERATION; CHECKPOINT KINASE 2; CYCLIN D1; DNA DAMAGE; DRUG REPOSITIONING; ENZYME ACTIVATION; G1 PHASE CELL CYCLE CHECKPOINTS; HUMANS; MALE; MICROSCOPY, FLUORESCENCE; NITROQUINOLINES; PROSTATIC NEOPLASMS; RETINOBLASTOMA PROTEIN; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84950159747     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.5655     Document Type: Article

References (53)

1. Shim JS, Liu JO. Recent advances in drug repositioning for the discovery of new anticancer drugs. Int J Biol Sci. 2014; 10:654-663.
2. Dakshanamurthy S, Issa NT, Assefnia S, Seshasayee A, Peters OJ, Madhavan S, Uren A, Brown ML, Byers SW. Predicting new indications for approved drugs using a proteochemometric method. J Med Chem. 2012; 55:6832-6848.
3. Stolz A, Ertych N, Bastians H. Tumor suppressor CHK2: regulator of DNA damage response and mediator of chromosomal stability. Clin Cancer Res. 2011; 17:401-405.
4. Antoni L, Sodha N, Collins I, Garrett MD. CHK2 kinase: cancer susceptibility and cancer therapy-two sides of the same coin? Nat Rev Cancer. 2003; 7:925-936.
5. Bartek J, Lukas J. Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell. 2003; 3:421-429.
6. Zhang J, Willers H, Feng Z, Ghosh JC, Kim S, Weaver DT, Chung JH, Powell SN, Xia F. Chk2 phosphorylation of BRCA1 regulates DNA double-strand break repair. Mol Cell Biol. 2004; 24:708-718.
7. Zhuang J, Zhang J, Willers H, Wang H, Chung JH, van Gent DC, Hallahan DE, Powell SN, Xia F. Checkpoint kinase 2-mediated phosphorylation of BRCA1 regulates the fidelity of nonhomologous end-joining. Cancer Res. 2006; 66:1401-1408.
8. Jack MT, Woo RA, Hirao A, Cheung A, Mak TW, Lee PW. Chk2 is dispensable for p53-mediated G1 arrest but is required for a latent p53-mediated apoptotic response. Proc Natl Acad Sci USA. 2002; 99:9825-9829.
9. Stevens C, Smith L, La Thangue NB. Chk2 activates E2F-1 in response to DNA damage. Nat Cell Biol. 2003; 5:401-409.
10. Ojuka EO. Role of calcium and AMP kinase in the regulation of mitochondrial biogenesis and GLUT4 levels in muscle. Proc Nutr Soc. 2004; 63:275-278.
11. Russo GL, Russo M, Ungaro P. AMP-activated protein kinase: a target for old drugs against diabetes and cancer. Biochem Pharmacol. 2013; 86:339-350.
12. Hardie DG. AMPK: positive and negative regulation, and its role in whole-body energy homeostasis. Curr Opin Cell Biol. 2014; 33C:1-7.
13. Hardie DG, Alessi DR. LKB1and AMPK and the cancermetabolism link-ten years after. BMC Biol. 2013; 11:36.
14. Lee CR, Chun JN, Kim SY, Park S, Kim SH, Park EJ, Kim IS, Cho NH, Kim IG, So I, Kim TW, Jeon JH. Cyclosporin A suppresses prostate cancer cell growth through CaMKKß/AMPK-mediated inhibition of mTORC1 signaling. Biochem Pharmacol. 2012; 84:425-431.
15. Colamonici M, Blyth G, Saleiro D, Szilard A, Bliss-Moreau M, Giles FJ, Altman JK, Beauchamp EM, Platanias LC. Dual targeting of acute myeloid leukemia progenitors by catalytic mTOR inhibition and blockade of the p110a subunit of PI3 kinase. Oncotarget. 2015; 6:8062-8070.
16. Pelletier C, Prognon P, Bourlioux P. Roles of divalent cations and pH in mechanism of action of nitroxoline against Escherichia coli strains. Antimicrob Agents Chemother. 1995; 39:707-713.
17. Jiang H, Taggart JE, Zhang X, Benbrook DM, Lind SE, Ding WQ. Nitroxoline (8-hydroxy-5-nitroquinoline) is more a potent anti-cancer agent than clioquinol (5-chloro-7-iodo-8-quinoline). Cancer Lett. 2011; 312:11-17.
18. Shim JS, Matsui Y, Bhat S, Nacev BA, Xu J, Bhang HE, Dhara S, Han KC, Chong CR, Pomper MG, So A, Liu JO. Effect of nitroxoline on angiogenesis and growth of human bladder cancer. J Natl Cancer Inst. 2010; 102:1855-1873.
19. Sosic I, Mirkovic B, Arenz K, Stefane B, Kos J, Gobec S. Development of new cathepsin B inhibitors: combining bioisosteric replacements and structure-based design to explore the structure-activity relationships of nitroxoline derivatives. J Med Chem. 2013; 56:521-533.
20. Giacinti C, Giordano A. RB and cell cycle progression. Oncogene. 2006; 25:5220-5227.
21. Sellers WR, Kaelin WG Jr. Role of the retinoblastoma protein in the pathogenesis of human cancer. J Clin Oncol. 1997; 15:3301-3312.
22. Fernandez-Vidal A, Mazars A, Manenti S. CDC25A: a rebel within the CDC25 phosphatases family?. Anticancer Agents Med Chem. 2008; 8:825-8231.
23. Vigo E, Müller H, Prosperini E, Hateboer G, Cartwright P, Moroni M C Helin K. CDC25A phosphatase is a target of E2F and is required for efficient E2F-induced S phase. Mol Cell Biol. 1999; 19:6379-6395.
24. Inoki K, Kim J, Guan KL. AMPK, and mTOR in cellular energy homeostasis and drug targets. Annu Rev Pharmacol Toxicol. 2012; 52:381-400.
25. Cuyàs E, Corominas-Faja B, Joven J, Menendez JA. Cell cycle regulation by the nutrient-sensing mammalian target of rapamycin (mTOR) pathway. Methods Mol Biol. 2014; 1170:113-144.
26. Hsueh YS, Chang HH, Chiang NJ, Yen CC, Li CF, Chen LT. MTOR inhibition enhances NVP-AUY922-induced autophagy-mediated KIT degradation and cytotoxicity in imatinib-resistant gastrointestinal stromal tumors. Oncotarget. 2014; 5:11723-11736.
27. Sui X, Chen R, Wang Z, Huang Z, Kong N, Zhang M, Han W, Lou F, Yang J, Zhang Q, Wang X, He C, Pan H. Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment. Cell Death Dis. 2013; 4:e838.
28. Tanida I, Waguri S. Measurement of autophagy in cells and tissues. Methods Mol Biol. 2010; 648:193-214.
29. Smith J, Tho LM, Xu N, Gillespie DA. The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer. Adv Cancer Res. 2010; 108:73-112.
30. Stolz A, Ertych N, Bastians H. Tumor suppressor CHK2: regulator of DNA damage response and mediator of chromosomal stability. Clin Cancer Res. 2011; 17:401-405.
31. Kuo LJ, Yang LX. Gamma-H2AX-a novel biomarker for DNA double-strand breaks. in vivo. 2008; 22:305-309.
32. Kao J, Milano MT, Javaheri A, Garofalo MC, Chmura SJ, Weichselbaum RR, Kron SJ. gamma-H2AX as a therapeutic target for improving the efficacy of radiation therapy. Curr Cancer Drug Targets. 2006; 6:197-205.
33. Haase H, Rink L. Zinc signals and immune function. Biofactors. 2014; 40:27-40.
34. He Y, Liu Z, Qiao C, Xu M, Yu J, Li G. Expression and significance of Wnt signaling components and their target genes in breast carcinoma. Mol Med Rep. 2014; 9:137-143.
35. Gautschi O, Ratschiller D, Gugger M, Betticher DC, Heighway J. Cyclin D1 in non-small cell lung cancer: a key driver of malignant transformation. Lung Cancer. 2007; 55:1-14.
36. Drobnjak M, Osman I, Scher HI, Fazzari M, Cordon-Cardo C. Overexpression of cyclin D1 is associated with metastatic prostate cancer to bone. Clin Cancer Res. 2000; 6:1891-1895.
37. Palmero I, Peters G. Perturbation of cell cycle regulators in human cancer. Cancer Surv. 1996; 27:351-367.
38. Bracho-Valdés I, Moreno-Alvarez P, Valencia-Martínez I, Robles-Molina E, Chávez-Vargas L, Vázquez-Prado J. mTORC1-and mTORC2-interacting proteins keep their multifunctional partners focused. IUBMB Life. 2011; 63:896-914.
39. Weng QP, Kozlowski M, Belham C, Zhang A, Comb MJ, Avruch J. Regulation of the p70 S6 kinase by phosphorylation in vivo. Analysis using site-specific anti-phosphopeptide antibodies. J Biol Chem. 1998; 273:16621-16629.
40. Fingar DC, Salama S, Tsou C, Harlow E, Blenis J. Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. Genes Dev. 2002; 16:1472-1487.
41. Xu G, Zhang W, Bertram P, Zheng XF, McLeod H. Pharmacogenomic profiling of the PI3K/PTEN-AKTmTOR pathway in common human tumors. Int J Oncol. 2004; 24:893-900.
42. Kinkade CW, Castillo-Martin M, Puzio-Kuter A, Yan J, Foster TH, Gao H, Sun Y, Ouyang X, Gerald WL, Cordon-Cardo C, Abate-Shen C. Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. J Clin Invest. 2008; 118:3051-3064.
43. Kremer CL, Klein RR, Mendelson J, Browne W, Samadzedeh LK, Vanpatten K, Highstrom L, Pestano GA, Nagle RB. Expression of mTOR signaling pathway markers in prostate cancer progression. Prostate. 2006; 66:1203-1212.
44. van Veelen W, Korsse SE, van de Laar L, Peppelenbosch MP. The long and winding road to rational treatment of cancer associated with LKB1/AMPK/TSC/mTORC1 signaling. Oncogene. 2011; 30:2289-2303.
45. Mizushima N. The role of the Atg1/ULK1 complex in autophagy regulation. Curr Opin Cell Biol. 2010; 22:132-139.
46. Kim J, Kundu M, Viollet B, Guan KL. AMPK, and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat Cell Biol. 2011; 13:132-141.
47. Viry E, Paggetti J, Baginska J, Mgrditchian T, Berchem G, Moussay E, Janji B. Autophagy: An adaptive metabolic response to stress shaping the antitumor immunity. Biochem Pharmacol. 2014; 92:31-42.
48. Zhang JW, Zhang SS, Song JR, Sun K, Zong C, Zhao QD, Liu WT, Li R, Wu MC, Wei LX. Autophagy inhibition switches low-dose camptothecin-induced premature senescence to apoptosis in human colorectal cancer cells. Biochem Pharmacol. 2014; 90:265-275.
49. Falck J, Mailand N, Syljuåsen RG, Bartek J, Lukas J. The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis. Nature. 2001; 410:842-847.
50. Sanli T, Storozhuk Y, Linher-Melville K, Bristow RG, Laderout K, Viollet B, Wright J, Singh G, Tsakiridis T. Ionizing radiation regulates the expression of AMPactivated protein kinase (AMPK) in epithelial cancer cells: modulation of cellular signals regulating cell cycle and survival. Radiother Oncol. 2012; 102:459-465.
51. Sanli T, Steinberg GR, Singh G, Tsakiridis T. AMP-activated protein kinase (AMPK) beyond metabolism: a novel genomic stress sensor participating in the DNA damage response pathway. Cancer Biol Ther. 2014; 15:156-169.
52. de Lange J, Verlaan-de Vries M, Teunisse AF, Jochemsen AG. Chk2 mediates RITA-induced apoptosis. Cell Death Differ. 2012; 19:980-989.
53. Chen CR, Wang W, Rogoff HA, Li X, Mang W, Li CJ. Dual induction of apoptosis and senescence in cancer cells by Chk2 activation: checkpoint activation as a strategy against cancer. Cancer Res. 2005; 65:6017-6021.